Jevtana
Payments companies reported to CMS as associated with Jevtana. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Jevtana, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Jevtana
These are the largest totals companies reported as associated with Jevtana. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Devesh Pandya | Houston, TX | Hematology & Oncology | $18,315.08 |
| Stephen Freedland | West Hollywood, CA | Urology | $16,166.80 |
| Dale Shepard | Cleveland, OH | Hematology & Oncology | $11,786.51 |
| Pedro Barata | New Orleans, LA | Hematology & Oncology | $10,989.47 |
| Daniel Petrylak | New Haven, CT | Medical Oncology | $9,446.60 |
| Alicia Morgans | Boston, MA | Medical Oncology | $8,921.50 |
| Susan Slovin | New York, NY | Internal Medicine | $8,428.38 |
| Alan Bryce | Scottsdale, AZ | Hematology & Oncology | $8,365.76 |
| Edward Uchio | Orange, CA | Urology | $8,221.21 |
| Edwin Posadas | Burr Ridge, IL | Hematology & Oncology | $8,123.33 |
Prescribed Jevtana?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.